ALX Oncology
(NASDAQ) ALXO
ALX Oncology Financials at a Glance
Market Cap
$313.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$88.87M
EPS (TTM)
-$1.49
P/E Ratio
-1.56
Dividend
$0.00
Beta (Volatility)
1.50 (High)
Dividend
$0.00
Beta (Volatility)
1.50 (High)
Price
$2.06
Volume
776,526.82
Open
$2.33
Price
$2.06
Volume
776,526.82
Open
$2.33
Previous Close
$2.06
Daily Range
$2.05 - $2.41
52-Week Range
$0.44 - $2.66
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.50 (High)
Price
$2.06
Volume
776,526.82
Open
$2.33
Previous Close
$2.06
Daily Range
$2.05 - $2.41
52-Week Range
$0.44 - $2.66
Estimated Earnings Date
Aug 11, 2026
ALXO News
ALXO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout ALX Oncology
Industry
Biotechnology
Sector
Health CareEmployees
43
CEO
Jason Lettmann, MBA
Website
www.alxoncology.comHeadquarters
South San Francisco, CA 94080, US
ALXO Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-124.06%
Return on Capital
-333.42%
Return on Assets
-49.83%
Earnings Yield
-64.10%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$313.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
134.56M
Volume
776.53K
Avg. Volume
1.47M
Financials (TTM)
Gross Profit
-$150.00K
Operating Income
-$91.17M
EBITDA
-$86.70M
Operating Cash Flow
-$78.13M
Capital Expenditure
-$202.00K
Free Cash Flow
-$78.33M
Cash & ST Invst.
$140.32M
Total Debt
$5.22M
ALX Oncology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$150.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$313.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$7.29M
N/A
Employees
43
N/A
Net Income
-$17.93M
+41.7%
EBITDA
-$17.45M
+42.1%
Quarterly Fundamentals
Total Cash
$140.32M
+43.4%
Total Debt
$5.22M
-47.7%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$5.22M
+200.0%
Return on Assets
-49.83%
N/A
Return on Invested Capital
-57.65%
N/A
Free Cash Flow
-$18.70M
+24.4%
Operating Cash Flow
-$18.65M
+24.4%